291 results on '"Carson, Kenneth R."'
Search Results
2. Five hematologic tests and treatments to question
3. The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question
4. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
5. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
6. Engraftment Syndrome Incidence after Immune Checkpoint Inhibitor Therapy in Pts with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation: A Single Institutional Review
7. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
8. Approximating International Myeloma Working Group Uniform Response Criteria to Derive Response for Multiple Myeloma (MM) Patients Using Data from Electronic Health Records (EHR)
9. Real-World Application of National Comprehensive Cancer Network (NCCN) Testing Guidelines in Diffuse Large B-Cell Lymphoma (DLBCL) Results in Underdiagnosis of Double-Hit Lymphoma
10. Machine Learning Based Predictive Model of 5-Year Survival in Multiple Myeloma Autologous Transplant Patients
11. Outcomes in Multiple Myeloma Based on Comorbidities and Race
12. Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas
13. Cell of Origin (COO) Association with High Body Mass Index (BMI) and Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
14. Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score
15. Survival and Treatment of Black Patients with Chronic Lymphocytic Leukemia in the Veterans Health Affairs
16. Outcomes of Black Patients with Multiple Myeloma in the Veterans Health Administration
17. Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results
18. The Real-World Frequency of 24-Hour Urine Protein Electrophoresis (UPEP), Serum Free Light Chain (SFLC), and Serum Protein Electrophoresis (SPEP) Testing in Patients with Multiple Myeloma (MM)
19. Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM)
20. Hepatitis B Testing Rates in Patients with Chronic Lymphocytic Leukemia before and during Administration of Anti-CD20 Therapy
21. Outcomes of Chemotherapy Treatment in Elderly Patients with Hodgkin Lymphoma
22. Differential Outcome of Patients with Primary Refractory Vs. Relapsed Peripheral T-Cell Lymphoma: Analysis from a Prospective Multicenter US Cohort Study
23. The Role of HIV in Race-Based Differences in Diffuse Large B-Cell Lymphoma(DLBCL) Treatment and Outcomes
24. Application of a Validated Predictive Model for Venous Thromboembolism in Cancer to Patients with Multiple Myeloma
25. Treatment-Related Weight Change and Overall Survival in United States Veterans with Follicular Lymphoma
26. Statin Therapy Improves Multiple Myeloma (MM) Specific Surviva
27. Metformin Therapy and Survival in Multiple Myeloma Among US Veterans with Diabetes Mellitus
28. Previous Agent Orange Exposure Is Correlated with Worse Outcome in Patients with Multiple Myeloma (MM)
29. Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing
30. Risk of Myelodysplasia and Acute Myeloid Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine and Bendamustine
31. Post-MGUS Diagnosis Serum M-Protein Velocity and the Risk of Progression of MGUS to Multiple Myeloma
32. Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Positive (ALCL, ALK+): Data from 119 Patients Prospectively Registered in the International T-Cell Project
33. Aspirin May be Inadequate Thromboprophylaxis in Multiple Myeloma
34. Risk of Herpes Zoster in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine or Bendamustine
35. The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study
36. The Veterans Health Administration Provides Equal Access to Autologous Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma
37. Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL)
38. Racial Differences in Treatment Dose Intensity Among Patients with Diffuse Large B-Cell Lymphoma: Analysis of the Veterans Health Administration (VHA) National Database
39. Venous Thromboembolism Is Associated with Increased Mortality in Patients with Multiple Myeloma
40. Is Body Mass Index Related to the Progression of Monoclonal Gammopathy of Unknown Significance to Multiple Myeloma?
41. Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium
42. Venous Thromboembolism In Patients With Non-Hodgkin Lymphoma: Analysis Of The Veterans Health Administration (VHA) National Database
43. Clinical and Economic Burden Of Peripheral T-Cell Lymphoma In The United States
44. Treatment-Related Weight Change In United States Veterans With Non-Hodgkin Lymphoma
45. Zoledronic Acid Improves Overall Survival Compared To Pamidronate In Multiple Myeloma
46. Psoas Cross-Sectional Area As Radiographic Measure Of Sarcopenia Does Not Predict Overall Survival In Multiple Myeloma
47. Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients
48. First Estimates of Incidence of Progressive Multifocal Leukoencephalopathy Developing Among 10,459 Non-HIV Lymphoma VA Patients Who Receive Rituximab: Results From the Veterans Administration Database (1999–2012).
49. Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry
50. Impact of BMI On Treatment-Related Toxicity in United States Veterans with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CHOP+/−R.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.